Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.

World journal of gastroenterology - 14 Apr 2014

Wang Kai-Li, Xing Han-Qian, Zhao Hong, Liu Jun-Wei, Gao Deng-Lian, Zhang Xue-Hua, Yao Hong-Yu, Yan Li, Zhao Jun

Abstract excerpt

AIM: To evaluate the efficacy and tolerability of low-dose standard or pegylated interferon (PEG-IFN) in hepatitis C virus (HCV)-positive hemodialysis patients. METHODS: In total, 19 patients were enrolled in this study, of which 12 received PEG-IFNα-2a 67.5 μg 1 time/wk (Group 1) and 7 received standard interferon α-2b subcutaneously 1.5 × 10⁶ U 3 times/wk (Group 2). The treatment durations were 48 wk for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Erythropoietin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Kidney Failure, Chronic

Share to Polyethylene Glycols

Share to Renal Dialysis

Source

Open in PubMed Open full text

Identifiers

PMID: 24744598
DOI: 10.3748/wjg.v20.i14.4071
PMCID: PMC3983465

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.PMID 24744598Read ↗

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Semantic proximity Read ↗

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.Semantic proximity Read ↗

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Semantic proximity Read ↗

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.Semantic proximity Read ↗

Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Semantic proximity Read ↗

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Semantic proximity Read ↗

The Efficacy of the Direct-Acting Antiviral Combination in Hemodialysis Patients With Chronic Hepatitis C Virus Genotype 1 InfectionSemantic proximity Read ↗

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.Semantic proximity Read ↗

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.Semantic proximity Read ↗

Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Semantic proximity Read ↗

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.